What does DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE do?

DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE is a specialist medical practice in Boechout. Private Limited, started on 11 May 2011, 1 establishment.

What is the address of DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE?

The registered office of DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE is located at Guido Gezellestraat 20, 2530 Boechout.

Is DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE still active?

Yes. According to the CBE (28 September 2026) DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE is active, legal situation “Normale toestand”, started on 11 May 2011.

Is DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE registered on Peppol?

Yes, DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE is registered on the Peppol network with ID 0208:0836577389.

What is the enterprise number of DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE?

The enterprise number of DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE is BE0836577389.

When was DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE founded?

DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE was founded on 11 May 2011.

Who are the directors of DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE?

According to the 2025 annual accounts, the directors of DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE are: Sandra Demuynck.

Is DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 11 May 2011; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE make in 2025?

DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE posted a profit after taxes of € 134,850 in financial year 2025.

What is the revenue of DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE?

As a small company, DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 204,399.

DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE (Private Limited)

Dossier DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE, printed on 28 September 2026 from databakkes.be/en/0836577389/dokter-demuynck-endocrino-diabetologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE from Boechout, company number BE0836577389, closed financial year 2025 with a result of € 134,850 after tax. For that financial year DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE recorded a gross margin of € 204,399 and equity of € 370,001. Compared with financial year 2024, the result moved from € 130,891 to € 134,850. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 3, 2026.

What it is worth Growing

€ 370,001

▲ 1% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 134,850

▲ 3% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 181,403

▲ 63% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 131,864 paid out

98 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Vehicles and equipment

€ 8,319

▼ 5% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 9 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 81,776

▼ 10% vs 2024

€ 8,815 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.

Owed to suppliers

€ 4,337

▼ 75% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 42,588

▼ 3% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 172,928 Gross margin 2022: € 172,928 First fiscal year in the series	€ 177,012 Gross margin 2023: € 177,012 ▲ 2% vs 2022 (€ 172,928) Favourable step	€ 197,103 Gross margin 2024: € 197,103 ▲ 11% vs 2023 (€ 177,012) Favourable step	€ 204,399 Gross margin 2025: € 204,399 ▲ 4% vs 2024 (€ 197,103) Favourable step	▲ 4%
Profit after taxes	€ 110,057 Profit after taxes 2022: € 110,057 First fiscal year in the series	€ 114,063 Profit after taxes 2023: € 114,063 ▲ 4% vs 2022 (€ 110,057) Favourable step	€ 130,891 Profit after taxes 2024: € 130,891 ▲ 15% vs 2023 (€ 114,063) Favourable step	€ 134,850 Profit after taxes 2025: € 134,850 ▲ 3% vs 2024 (€ 130,891) Favourable step	▲ 3%
Equity	€ 231,634 Equity 2022: € 231,634 First fiscal year in the series	€ 272,283 Equity 2023: € 272,283 ▲ 18% vs 2022 (€ 231,634) Favourable step	€ 367,015 Equity 2024: € 367,015 ▲ 35% vs 2023 (€ 272,283) Favourable step	€ 370,001 Equity 2025: € 370,001 ▲ 1% vs 2024 (€ 367,015) Favourable step	▲ 1%
Total debts	€ 190,956 Total debts 2022: € 190,956 First fiscal year in the series	€ 215,508 Total debts 2023: € 215,508 ▲ 13% vs 2022 (€ 190,956) Unfavourable step	€ 188,716 Total debts 2024: € 188,716 ▼ 12% vs 2023 (€ 215,508) Favourable step	€ 128,701 Total debts 2025: € 128,701 ▼ 32% vs 2024 (€ 188,716) Favourable step	▼ 32%
Cash	€ 128,304 Cash 2022: € 128,304 First fiscal year in the series	€ 45,152 Cash 2023: € 45,152 ▼ 65% vs 2022 (€ 128,304) Unfavourable step	€ 111,040 Cash 2024: € 111,040 ▲ 146% vs 2023 (€ 45,152) Favourable step	€ 181,403 Cash 2025: € 181,403 ▲ 63% vs 2024 (€ 111,040) Favourable step	▲ 63%
Land & buildings	€ 156,817 Land & buildings 2022: € 156,817 First fiscal year in the series	€ 140,404 Land & buildings 2023: € 140,404 ▼ 10% vs 2022 (€ 156,817) Unchanged	€ 130,060 Land & buildings 2024: € 130,060 ▼ 7% vs 2023 (€ 140,404) Unchanged	€ 119,988 Land & buildings 2025: € 119,988 ▼ 8% vs 2024 (€ 130,060) Unchanged	▼ 8%
Retained profit	€ 219,234 Retained profit 2022: € 219,234 First fiscal year in the series	€ 259,883 Retained profit 2023: € 259,883 ▲ 19% vs 2022 (€ 219,234) Favourable step	€ 354,615 Retained profit 2024: € 354,615 ▲ 36% vs 2023 (€ 259,883) Favourable step	€ 357,601 Retained profit 2025: € 357,601 ▲ 1% vs 2024 (€ 354,615) Favourable step	▲ 1%
Dividend	€ 91,364 Dividend 2022: € 91,364 First fiscal year in the series	€ 73,414 Dividend 2023: € 73,414 ▼ 20% vs 2022 (€ 91,364) Unchanged	€ 36,160 Dividend 2024: € 36,160 ▼ 51% vs 2023 (€ 73,414) Unchanged	€ 131,864 Dividend 2025: € 131,864 ▲ 265% vs 2024 (€ 36,160) Unchanged	▲ 265%
Bank debt	€ 107,700 Bank debt 2022: € 107,700 First fiscal year in the series	€ 99,430 Bank debt 2023: € 99,430 ▼ 8% vs 2022 (€ 107,700) Favourable step	€ 90,956 Bank debt 2024: € 90,956 ▼ 9% vs 2023 (€ 99,430) Favourable step	€ 81,776 Bank debt 2025: € 81,776 ▼ 10% vs 2024 (€ 90,956) Favourable step	▼ 10%
Balance sheet total	€ 422,590 Balance sheet total 2022: € 422,590 First fiscal year in the series	€ 487,791 Balance sheet total 2023: € 487,791 ▲ 15% vs 2022 (€ 422,590) Unchanged	€ 555,731 Balance sheet total 2024: € 555,731 ▲ 14% vs 2023 (€ 487,791) Unchanged	€ 498,702 Balance sheet total 2025: € 498,702 ▼ 10% vs 2024 (€ 555,731) Unchanged	▼ 10%

Key figures of DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE?

What happened at DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 3, 2026 New annual accounts for financial year 2025: profit of € 134,850 (▲ 3% vs 2024). Source: NBB ↗
May 11, 2011 New establishment in Boechout. KBO
May 11, 2011 Start of the company according to the CBE. KBO

In short

From € 110,057 profit in 2022 to € 134,850 profit in 2025.

Paid € 204,434 in corporate taxes since 2022.

Best year ever: 2025, with € 134,850 profit.

Paid out € 332,801 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE? We notify you, reason included.

Follow DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Sandra Demuynck

DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE

Behind DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE is Sandra Demuynck.

See the full network in the app

Directors

According to the 2025 annual accounts

Sandra Demuynck

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Guido Gezellestraat 20

2530 Boechout

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0836.577.389
VAT number: BE 0836.577.389
Registered office: Guido Gezellestraat 20, 2530 Boechout
Names & denominations: DOKTER DEMUYNCK ENDOCRINO - DIABETOLOGIE
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 11 May 2011
Peppol: Active · Active since 24 Jul 2024
Contact: [email protected]
Activities · NACE: Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗